Format

Send to

Choose Destination
Cell Metab. 2016 Feb 9;23(2):231-3. doi: 10.1016/j.cmet.2016.01.010.

Regulatory T Cell Immunotherapy for Type 1 Diabetes: A Step Closer to Success?

Author information

1
Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris 75006, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris 75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris 75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathologie et immuno-intervention thérapeutique, Paris 75006, France. Electronic address: jagadeesh.bayry@crc.jussieu.fr.
2
Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris 75006, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris 75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris 75006, France; Centre de Recherche des Cordeliers, Equipe - Pathogenèse cellulaire et clinique du diabète, Paris 75006, France; Service de Diabétologie, Endocrinologie, Nutrition, Centre Universitaire du Diabète et de ses Complications, Hôpital Lariboisière, University Paris-Diderot Paris-7, Paris 75010, France.

Abstract

Regulatory T cell (Treg) therapy has shown promises in experimental models of type 1 diabetes (T1D) and other autoimmune diseases. Now, Bluestone et al. (2015) report in a phase 1, dose-escalation study that ex vivo-expanded autologous polyclonal Treg therapy is safe and well tolerated in adult patients with recent-onset T1D.

PMID:
26863486
DOI:
10.1016/j.cmet.2016.01.010
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center